These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38058274)

  • 1. Anti-Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis.
    Cappelli LC; Hines D; Wang H; Bingham CO; Darrah E
    ACR Open Rheumatol; 2024 Feb; 6(2):81-90. PubMed ID: 38058274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
    Darrah E; Yu F; Cappelli LC; Rosen A; O'Dell JR; Mikuls TR
    Arthritis Rheumatol; 2019 May; 71(5):696-702. PubMed ID: 30507066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
    Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
    Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
    Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
    Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
    Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
    Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
    Gómez-Bañuelos E; Shi J; Wang H; Danila MI; Bridges SL; Giles JT; Sims GP; Andrade F; Darrah E
    Arthritis Rheumatol; 2022 Nov; 74(11):1746-1754. PubMed ID: 35675168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival.
    Wilson TM; Solomon JJ; Humphries SM; Swigris JJ; Ahmed F; Wang H; Darrah E; Demoruelle MK
    Am J Med Sci; 2023 Jun; 365(6):480-487. PubMed ID: 36918112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
    Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
    J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
    Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
    Front Immunol; 2018; 9():2696. PubMed ID: 30515171
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-protein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis.
    Palterer B; Vitiello G; Del Carria M; D'Onofrio B; Martinez-Prat L; Mahler M; Cammelli D; Parronchi P
    Rheumatology (Oxford); 2023 Jul; 62(7):2410-2417. PubMed ID: 36440916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
    Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
    Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
    Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
    Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
    Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
    Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
    Zhao J; Zhao Y; He J; Jia R; Li Z
    J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
    Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
    Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis.
    Zhang G; Xu J; Du D; Liu Y; Dai L; Zhao Y
    Rheumatology (Oxford); 2024 Apr; 63(4):914-924. PubMed ID: 37824204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
    Giles JT; Darrah E; Danoff S; Johnson C; Andrade F; Rosen A; Bathon JM
    PLoS One; 2014; 9(6):e98794. PubMed ID: 24901704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.